Literature DB >> 10088958

Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer.

O Onur1, R Celiker.   

Abstract

Bacillus Calmette-Guerin (BCG) is the most effective agent currently available for the treatment of superficial bladder cancer. However, this form of treatment is associated with some complications, including arthritis. In this report, we present a 69-year-old woman who developed inflammatory polyarthritis following BCG treatment for superficial bladder cancer. The arthritis resolved following treatment with a non-steroidal anti-inflammatory drug and chloroquinine.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10088958     DOI： 10.1007/s100670050059

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  4 in total

Review 1.  Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.

Authors:  Elisa Tinazzi; Vincenzo Ficarra; Sara Simeoni; Walter Artibani; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2005-10-12       Impact factor: 2.631

2.  Reactive arthritis following BCG immunotherapy for bladder carcinoma.

Authors:  Elisa Tinazzi; Vincenzo Ficarra; Sara Simeoni; Dimitri Peterlana; Claudio Lunardi
Journal:  Clin Rheumatol       Date:  2005-01-20       Impact factor: 2.980

3.  Complications of intravesical bacillus calmette-guérin.

Authors:  Liam C Macleod; Tin C Ngo; Mark L Gonzalgo
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

Review 4.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.